<DOC>
	<DOCNO>NCT02183324</DOCNO>
	<brief_summary>Study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics BI 1356 BS ( 0.5 mg , 2.5 mg , 10 mg ) administer orally daily 28 day Japanese patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>BI 1356 BS Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Japanese patient diagnosis type 2 diabetes mellitus treat diet and/or exercise one two oral hypoglycaemic agent except glitazones Glycosylated haemoglobin A1 ( HbA1c ) &lt; = 8.5 % screen patient treat diet and/or exercise and/or one oral hypoglycaemic agent &lt; = 8.0 % screen patient treat two oral hypoglycaemic agent Age ≥21 ≤ 70 year BMI ≥ 17.6 ≤ 35 kg/m2 Any finding medical examination include blood pressure , pulse rate electrocardiogram ( ECG ) deviate normal acceptable clinical relevance Clinically relevant concomitant disease like renal insufficiency , cardiac insufficiency ( NYHA IIIV ) , know cardiovascular disease include hypertension ( &gt; 150/95 mmHg ) , stroke , transient ischemic attack ( TIA ) . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , except type 2 diabetes mellitus , hyperlipidaemia medically treat hypertension Diseases central nervous system ( epilepsy ) psychiatric disorder relevant neurological disorder except polyneuropathy Chronic relevant acute infection ( e.g. , human immunodeficiency virus ( HIV ) , hepatitis ) History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug drug administration except antihypertensive , acetylsalicylic acid , statin Use drug decrease blood glucose within 10 day drug administration Participation another trial investigational drug within two month drug administration Alcohol abuse Drug abuse Blood donation ( 100 mL within four week drug administration ) Excessive physical activity ( within one week drug administration trial ) Any laboratory value outside reference range clinical relevance acceptable ( value three time higher upper limit normal range , e.g. , liver enzymes aspartate aminotransferase ( AST ( serum glutamate oxaloacetate transaminase/ SGOT ) ) , alanine transaminase ( ALT ( serum glutamate pyruvate transaminase/ SGPT ) ) , alkaline phosphatase ( γALP ) , lactate dehydrogenase ( LDH ) Fasted blood glucose &gt; 240 mg/dL ( =13.3 mmol/L ) two consecutive day washout Serum creatinine 1.3 mg/dL screen Pregnancy childbearing potential patient breastfeed patient Not willing use adequate contraception ( condom use plus another form contraception , e.g. , spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole study period time first intake study drug one month last intake</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>